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1 Introduction
High levels of corticotropin releasing factor im-
munoactivity (CRFi), a hypothalamic releasing
hormone which stimulates pituitary ß-endor-
phin (ß-EP) and ACTH secretion, are present
in the plasma of women during the second half
of pregnancy [2, 7]. This is in distinction to the
undetectable or extremely small amounts of the
hypothalamic releasing factor which have been
reported in the peripheral plasma of healthy
non-pregnant adults [9]. The CRFi measurable
in the plasma of non-pregnant adults appears
to be of hypothalamic origin [9] while there are
several lines of evidence to support a placental
source for the CRFi measured in the plasma
during pregnancy.
A substance similar in molecular weight to
CRF has been extracted from term human pla-
centas which causes the release of ACTH and
ß-EP from rat anterior pituitary cells in culture
[8]. In addition, we have found a highly signifi-
cant correlation between simultaneously ob-
tained maternal and fetal CRFi levels at deliv-
ery as well as a higher CRFi concentration in
the umbilical vein compared to the umbilical
artery, again suggesting a placental source for
both maternal and fetal CRFi [2]. These results,
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together with the disappearance of CRFi from
maternal plasma within 24 hours after delivery
[2, 7], provide strong evidence that the placenta
secretes CRFi into the maternal and fetal circu-
lations during gestation.
Little is known about the regulation of this
placental CRFi during pregnancy. We have pre-
viously reported that umbilical cord plasma
ACTH and ß-EP are inversely correlated with
pU2 and pH [11] while no significant relation-
ship was observed between fetal plasma CRFi
and pH [2] suggesting that in the fetus, hypoxia
and acidosis are not stimuli for increased CRFi
release by the placenta. In the present study,
we have examined the effects of an acute dose
of betamethasone, a long-acting corticosteroid,
on maternal plasma CRFi as well as ACTH
and cortisol levels. Several studies have sup-
ported the concept that glucocorticoids exert
their negative feedback effect at both a pituitary
and a hypothalamic level [4, 6, 10]. We have
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undertaken the present study to investigate
whether glucocorticoids similarly suppress the
release of CRFi by the placenta during preg-
nancy.
2 Methods
Eleven pregnant women at 28 — 32 weeks gesta-
tion were hospitalized for premature labor and
treated with betamethasone to induce fetal lung
maturation. Five of the 11 patients received
tocolytic agents as well. Baseline 8 A.M.
plasma samples were drawn for CRFi, ACTH
and cortisol measurements. Betamethasone 12
mgs was given intramuscularly to these patients
at 11 P. M. and CRFi, ACTH and cortisol were
again measured at 8 A. M. the following morn-
ing.
CRFi was extracted from 1 ml plasma with
Sep-pak C-18 cartridges (Waters Associates,
Milford, MA) and measured by RIA using anti-
serum to human CRF raised in this laboratory.
Assay sensitivity was lOpg/tube and 44 pg/ml
when 1 ml of plasma was extracted. ACTH was
extracted from 2 ml plasma with talc tablets as
described previously [3] and measured by RIA
using synthetic human ACTH and the West
antiserum supplied by the National Pituitary
Agency. Cortisol was measured by competitive
protein binding.
Samples were collected in ice-chilled glass tubes
containing EDTA (for CRF determinations) or
heparin (for ACTH and cortisol measurements)
and were immediately centrifuged at 4°C.
Plasma was either extracted for assay immedi-
ately or frozen at —20 °C and thawed once for
assay within 2 weeks.
3 Results
Before the administration of betamethasone,
the mean (+ SEM) plasma cortisol concentra-
tion was 21.9 ± 3 ug/dl, mean plasma ACTH
concentration was 45.4 + 6.4 pg/ml and mean




* p < .05
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Figure 1. Effect of betamethasone on cortisol, ACTH,
and CRFi concentrations in maternal plasma.
Mean maternal plasma ACTH and cortisol
levels were significantly depressed after betame-
thasone administration while plasma CRFi re-
mained unchanged. The mean maternal post-
betamethasone ACTH concentration fell to
25.4 ± 5.2 pg/ml (p < 0.05) and the mean
cortisol level fell to 9.5 ± 1.2 ug/dl (p < 0.01).
Mean maternal plasma CRFi concentration
after betamethasone was 214 + 69 pg/ml with
a range of 48 —835 pg/ml.
There was no significant correlation between
maternal plasma CRFi and ACTH or cortisol
concentrations. As expected there was a highly
significant correlation between maternal
plasma ACTH and cortisol levels (figure 2).
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Figure 2. Correlation of ACTH and cortisol levels in
maternal plasma.
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4 Discussion
In this study we report that the administration
of betamethasone to pregnant women does not
inhibit the placental secretion of CRFi into
maternal plasma. Thus, the acute regulation of
placental CRFi appears to be distinct from that
of hypothalamic CRF. Several investigators
have shown that glucocorticoids have inhibi-
tory effects on both pituitary ACTH and hypo-
thalamic CRF accounting for the suppression
of cortisol secretion. ROBERTS et al. [6] have
shown that the production of the proopiome-
lanocortin derived peptides, such as ACTH, is
under direct negative control by glucocorti-
coids. An effect of glucocorticoids on CRF was
demonstrated by SUDA et al. who reported that
the acute administration of dexamethasone to
rats caused a significant decrease in the hypo-
thalamic CRF content [10] while in a more
recent study, JINGAMI et al. reported that dexa-
methasone administered to adrenalectomized
rats lowered the messenger RNA for the CRF
precursor in the hypothalamus [4]. Our finding
that glucocorticoids to not inhibit placental
CRF release only reflects the effects of a single
dose of betamethasone. The effect of chronic
treatment with glucocorticoids remains un-
known.
Summary
Corticotropin releasing factor immunoactivity (CRFi)
has been identified in the plasma of women in the second
half of gestation. There are several lines of evidence
supporting a placental source for this hormone. Regula-
tion of placental CRFi is poorly understood. In this
study, the effect of a long-acting glucorticoid on the
release of placental CRFi was investigated.
Eleven women in the third trimester of pregnancy had
plasma samples measured for CRFi, ACTH and cortisol
We also report a lack of correlation between
CRFi and either ACTH or cortisol in maternal
plasma during pregnancy. However, although
the biological activity and physiologic signifi-
cance of this CRFi is unknown, this lack of
correlation does not exclude the possibility that
placental CRFi influences ACTH and cortisol
secretion during pregnancy. It is possible that
placental CRFi is playing a permissive role in
causing ACTH release in response to hypotha-
lamic CRF.
The highly significant correlation between ma-
ternal ACTH and cortisol levels, with slightly
elevated cortisol levels, is in agreement with the
results of previous reports [1, 5].
In summary, we report that high levels of CRFi
are present in maternal plasma in the final
weeks of gestation and have previously shown
that CRFi becomes detectable at 18 weeks of
gestation, increases progressively with advanc-
ing gestational age, and disappears from ma-
ternal plasma within 24 hours after delivery
[2]. This placental CRFi is not suppressed by
betamethasone, while maternal plasma ACTH
and cortisol levels are lowered by the adminis-
tration of this long-acting glucocorticoid. These
results suggest that the acute regulation of pla-
cental CRFi is distinct from the regulation of
hypothalamic CRF.
before and after receiving 12 mg betamethasone. There
was a significant decrease in ACTH (p < 0.05) and
cortisol levels (p < 0.01) but no change in CRFi. It is
concluded that the secretion of CRFi by the placenta is
not inhibited by the administration of betamethasone
while maternal levels of cortisol and ACTH are lowered.
These results suggest that the acute regulation of placen-
tal CRFi is distinct from the regulation of hypothalamic
CRF.
Keywords: ACTH, betamethasone, corticotropin releasing factor, cortisol, CRF, glucocorticoids, placenta, preg-
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Zusammenfassung
Einfluß von Betamethason auf die maternalen Plasmaspie-
gel von Kortikotropin-Releasing-Faktor, ACTH und Kor-
tisol während der Schwangerschaft
In der zweiten Schwangerschaftshälfte konnte im Plasma
schwangerer Frauen ein Kortikotropin-Releasing-Fak-
tor mit Immunaktivität (CRFi) nachgewiesen werden.
Es gibt mehrere Hinweise auf die Plazenta als Synthe-
seort. Über welche Regulationsmechanismen dieses Hor-
mon gebildet wird, ist nicht bekannt. In der vorliegenden
Studie wurde der Einfluß eines langwirkenden Gluko-
kortikoids auf die Freisetzung von plazentarem CRFi
untersucht.
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Bei 11 Frauen im letzten Schwangerschaftstrimenon
wurden die Plasmaspiegel von CRFi, ACTH und Korti-
sol vor und nach Gabe von 12 mg Betamethason be-
stimmt. Beim ACTH- und Kortisolspiegel kam es zu
einem signifikanten Abfall (p < 0.05 bzw. p < 0.01),
der CRFi-Spiegel blieb unverändert. Wir schließen dar-
aus, daß die Bildung von CRFi in der Plazenta nach
Gabe von Betamethason nicht inhibiert wird, während
die materaalen Plasmaspiegel von Cortisol und ACTH
gesenkt werden. Die Ergebnisse zeigen, daß die Regula-
tion des plazentaren CRFi unabhängig von der Regula-
tion des hypothalamischen CRF erfolgt.
Schlüsselwörter: ACTH, Betamethason, CRF, Kortikotropin-Releasing-Faktor, Kortisol, Glukokortikoide, Pla-
zenta, Schwangerschaft.
Resume
Effets de la betamethasone sur le corticotropin releasing
factor, 1 . C. T. H. et le cortisol maternels plasmatiques
pendant la grossesse
On a identifie l'activite immunologique du corticotropin
releasing factor (C.R.F.i.) dans le plasma de femmes
dans la seconde moitie de la grossesse. II existe plusieurs
types de preuves montrant qu'il existe une origine pla-
centaire de cette hormone. On comprend mal la regula-
tion du C.R.F.i placentaire. Dans cette etude, on a
explore 1'effet d'un glucocortico'ide a action prolongee
sur la liberation du C. R. F. i placentaire.
Mots-cles:
On a mesure au cours du troisieme trimestre de la
grossesse de 11 femmes les taux plasmatiques de
C.R.F.i., d'A.C.T.H. et de cortisol avant et apres 12
mg de betamethasone. II y a une diminution significative
des taux d'A. C. T. H. (p < 0,05) et de cortisol (p < 0,01)
mais pas de modification du C. R. F. i. On en conclut
que le C. R. F. i d'origine placentaire n'est pas inhibe par
Fadministration de betamethasone alors que les taux
maternels et d'A. T. C. H. sont abaisses.
Ces resultats suggerent que la regulation fine du
C.R.F.i. placentaire est distincte de la regulation du
C. R. F. hypothalamique.
A. C. T. H., betamethasone, Corticotropin releasing factor, cortisol, C. R. F, glucocorticoi'des, grossesse,
placenta.
Acknowledgements: This work was supported by USP Health Service Grant HD06585 and 2 P50 HD13063.
The authors would like to thank Drs. INGE DYRENFURTH and WYLIE HEMBREE for performing the cortisol
determinations.
References
[1] ABOU-SAMRA AB, M PUGEAT, H DECHAUD, L NA-
CHURY, B BOUCHAREB, M FEVRE-MONTANGE, J
TOURNIAIRE: Increased plasma concentration of N-
terminal ß-lipotrophin and unbound cortisol during
pregnancy. Clin Endocrinol 20 (1984) 221
[2] GOLAND RS, SL WARDLAW, RI STARK, LS BROWN,
AG FRANTZ: High levels of corticotropin releasing
factor immunoactivity in maternal and fetal plasma
during pregnancy. J Clin Endocrinol Metab (in
press)
[3] GOLAND RS, SL WARDLAW, RI STARK, AG
FRANTZ: Human plasma ß-endorphin during preg-
nancy, labor and delivery. J Clin Endocrinol Metab
52 (1981) 74
[4] JINGAMI H, S MATSUKURA, S NUMA, H IMURA:
Effects of adrenalectomy and dexamethasone ad-
ministration on the levels of prepro-corticotropin
releasing factor messenger ribonucleic acid
(mRNA) in the hypothalamus and adrenocortico-
tropin/ß-lipotropin precursor mRNA in the pituit-
ary of rats. Endocrinology 117 (1985) 1314
[5] REES LH, CW BURKE, T CHARD, SW EVANS, L
LETCHWORTH: Possible placental origin of ACTH
in normal pregnancy. Nature 254 (1975) 620
[6] ROBERTS JL, CLC CHEN, JH EBERWINE, MJQ Ev-
INGER, E HERBERT, BS SCHACHTER: Glucocorticoid
regulation of proopiomelanocortin gene expression
in rodent pituitary. Recent Prog Horm Res 38
(1982) 227
[7] SASAKI A, AS LIOTTA, MM LUCKEY, AN MAR-
GIORIS, T SUDA, DT KRIEGER: Immunoreactive cort-
icotropin-releasing factor is present in human ma-
ternal plasma during the third trimester of preg-
nancy. J Clin Endocrinol Metab 59 (1984) 812
[8] SHIBASAKI T, E ODAGIRI, K SHIZUME, N LING: Cort-
icotropin-releasing factor-like activity in human
placental extracts. J Clin Endocrinol Metab 55
(1982) 384
[9] SUDA T, NI TOMORI, F YAJIMA, T SUMITOMO,
NAKAGAMI, T USHIYAMA, H DEMURA: Immunoreac-
tive corticotropin releasing factor in human plasma.
J. Perinat. Med, 15 (1987)
Tropper et al, Placental corticotropin releasing factor immunoactivity 225
The program of the sixty-seventh meeting of the [11] WARDLAW SL, RI STARK, L BAXI, AG FRANTZ:
Endocrine Society, Baltimore, MD, June 19—22, Plasma B-endorphin and B-lipotropin in the human
1985, Abstract 991 fetus at delivery: correlation with arterial pH and
[10] SUDA T, N TOMORI, F TOZAWA, T MOURI, H DE- pO2. J Clin Endocrinol Metab 44 (1979) 888
MURA, K SHIZUME: Effect of dexamethasone on Received June 30, 1986. Accepted August 10, 1986.
immunoreactive corticotropin-releasing factor in
the rat median eminence and intermediate-posterior _,r", °, !n ' . ° an _ „ __. . . , _
pituitary. Endocrinology 114 (1984) 851 Columbia University College of Physicians and Surgeons
*
 J
 &j \ ; Department of Medicine
630 W.I 68th Street
New York, N. Y. 10032, U. S. A.





Proceedings of the Fourth International Workshop
Neuherberg, Federal Republic of Germany, April 1986
Editors P. Brätter - P. Schramel
1987.17 cm 24 cm. XIII, 630 pages. Numerous illustrations.
Cloth DM 295,-; approx. US $155.50 ISBN 311010905 0
The proceedings of the 4th Workshop deal with new developments in the
trace element analysis of biological materials as well as with current problems
in trace element metabolism, nutrition, diagnosis and the therapy of trace
element related diseases.
Contents (Main Chapters)
Models for Trace Element Metabolism · Trace Element in Nutrition · Trace
Element Interactions · Trace Element Analysis of Body Fluids and Tissue
Samples · Significance of Trace Elements in Medicine · List of Participants ·
Author Index · Subject Index.
>A/so available
Trace Element Analytical Chemistry in Medicine and Biology
Volume 1:1980. XV, 851 pages. DM 180,-; approx. US $95.00
Volume 2:1983. XX, 1189 pages. DM 280,-; approx. US $147.50
Volume 3:1984. XVI, 763 pages. DM 240,-; approx. US $126.50




de Gruyter · Berlin · New York
